Lexicon Pharmaceuticals (LXRX) News Today $0.70 -0.04 (-5.91%) Closing price 04:00 PM EasternExtended Trading$0.70 +0.00 (+0.27%) As of 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock LXRX Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Lexicon Pharmaceuticals surges 67% following InvestingPro's Fair Value signalJune 8 at 7:58 AM | investing.comLexicon Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare ConferenceMay 29, 2025 | globenewswire.comWoodline Partners LP Lowers Stock Holdings in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)Woodline Partners LP cut its stake in shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Free Report) by 81.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 229,376 shares of the biopharmaceutical company's stock after sellinMay 29, 2025 | marketbeat.comLexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Receives Average Rating of "Hold" from AnalystsLexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Get Free Report) has been assigned a consensus rating of "Hold" from the five analysts that are currently covering the firm, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold recommendation and two have assigned aMay 23, 2025 | marketbeat.comPoint72 Asset Management L.P. Acquires 7,758,371 Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)Point72 Asset Management L.P. increased its holdings in shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Free Report) by 630.7% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 8,988,421 shares of the biopharmaceutical cMay 22, 2025 | marketbeat.comLexicon Pharmaceuticals, Inc. (LXRX): Analysts See 285% Upside PotentialMay 21, 2025 | insidermonkey.comLexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Stock Holdings Lifted by Tang Capital Management LLCTang Capital Management LLC lifted its holdings in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Free Report) by 750.3% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 850,268 shares of the biopharmaceutical company's stock after buying an aMay 21, 2025 | marketbeat.comLexicon Pharmaceuticals’ Sotagliflozin: Promising Phase 3 Developments Justify Buy RatingMay 20, 2025 | tipranks.comSONATA-HCM Study Design Presented at Heart Failure 2025, the Annual Congress of the Heart Failure Association of the European Society of CardiologyMay 19, 2025 | globenewswire.comLexicon Pharmaceuticals, Inc.: Lexicon Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business UpdatesMay 19, 2025 | finanznachrichten.deLexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Reported Earnings Last Week And Analysts Are Already Upgrading Their EstimatesMay 17, 2025 | finance.yahoo.comLexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q1 2025 Earnings Call TranscriptMay 15, 2025 | msn.comLexicon targets late 2025 Phase 3 start for pilavapadin and expands LX9851 partnership with Novo NordiskMay 14, 2025 | msn.comLexicon Pharmaceuticals Inc (LXRX) Q1 2025 Earnings Call Highlights: Strategic Partnerships and ...May 14, 2025 | gurufocus.comQ1 2025 Lexicon Pharmaceuticals Inc Earnings Call TranscriptMay 14, 2025 | gurufocus.comLexicon Pharmaceuticals (LXRX) Secures Major Licensing Deal with Novo NordiskMay 13, 2025 | gurufocus.comLexicon Pharmaceuticals, Inc. (LXRX) Q1 2025 Earnings Call TranscriptMay 13, 2025 | seekingalpha.comLexicon Pharmaceuticals Inc (LXRX) Q1 2025 Earnings: EPS Beats Estimates at -$0. ...May 13, 2025 | gurufocus.comLexicon Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business UpdatesMay 13, 2025 | globenewswire.comLexicon Pharmaceuticals Q1 2025 Earnings PreviewMay 12, 2025 | msn.comLexicon Pharmaceuticals to Present at the 3rd Annual H.C. Wainwright BioConnect Investor ConferenceMay 6, 2025 | gurufocus.comLexicon Pharmaceuticals to Present at the 3rd Annual H.C. ...May 6, 2025 | gurufocus.comLexicon Pharmaceuticals to Present at the 3rd Annual H.C. Wainwright BioConnect Investor ConferenceMay 6, 2025 | globenewswire.comLexicon Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025May 6, 2025 | gurufocus.comLexicon Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025May 6, 2025 | globenewswire.comSchonfeld Strategic Advisors LLC Has $5.58 Million Position in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)Schonfeld Strategic Advisors LLC increased its holdings in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Free Report) by 301.5% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 7,558,621 shares of the biopharMay 5, 2025 | marketbeat.comBoothbay Fund Management LLC Purchases Shares of 480,822 Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)Boothbay Fund Management LLC acquired a new position in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 480,822 shares of the biopharmaceutical company's stock,May 4, 2025 | marketbeat.comNantahala Capital Management LLC Acquires 4,300,000 Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)Nantahala Capital Management LLC grew its holdings in shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Free Report) by 186.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 6,604,150 shares of the bApril 30, 2025 | marketbeat.comLexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Given Consensus Recommendation of "Hold" by AnalystsLexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Get Free Report) has earned a consensus recommendation of "Hold" from the five brokerages that are covering the stock, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold recommendation and two have assigned a buy recommApril 28, 2025 | marketbeat.comLexicon Pharmaceuticals (LXRX) to Post Quarterly Earnings on ThursdayLexicon Pharmaceuticals (NASDAQ:LXRX) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 1. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-1-lexicon-pharmaceuticals-inc-stock/)April 26, 2025 | marketbeat.comLexicon Pharmaceuticals (NASDAQ:LXRX) Now Covered by Analysts at StockNews.comStockNews.com assumed coverage on Lexicon Pharmaceuticals in a research note on Monday. They issued a "sell" rating on the stock.April 22, 2025 | marketbeat.comLexicon Pharmaceuticals (NASDAQ:LXRX) Coverage Initiated at StockNews.comStockNews.com assumed coverage on shares of Lexicon Pharmaceuticals in a report on Sunday. They set a "sell" rating for the company.April 14, 2025 | marketbeat.comStockNews.com Begins Coverage on Lexicon Pharmaceuticals (NASDAQ:LXRX)StockNews.com started coverage on Lexicon Pharmaceuticals in a research report on Saturday. They issued a "sell" rating for the company.April 6, 2025 | marketbeat.comLexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Short Interest UpdateLexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Get Free Report) was the target of a large drop in short interest in the month of March. As of March 15th, there was short interest totalling 39,260,000 shares, a drop of 17.3% from the February 28th total of 47,460,000 shares. Currently, 17.1% of the company's shares are sold short. Based on an average daily trading volume, of 6,260,000 shares, the days-to-cover ratio is currently 6.3 days.April 3, 2025 | marketbeat.comLexicon Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare ConferenceApril 2, 2025 | globenewswire.comLexicon Pharmaceuticals' (LXRX) Buy Rating Reaffirmed at HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $4.00 target price on shares of Lexicon Pharmaceuticals in a research report on Friday.March 29, 2025 | marketbeat.comLexicon Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:LXRX)Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Get Free Report) saw unusually large options trading on Friday. Stock traders bought 2,504 call options on the company. This represents an increase of 61% compared to the average volume of 1,558 call options.March 29, 2025 | marketbeat.comStock Traders Purchase Large Volume of Lexicon Pharmaceuticals Call Options (NASDAQ:LXRX)Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Get Free Report) was the target of some unusual options trading activity on Friday. Stock traders acquired 2,504 call options on the company. This represents an increase of 61% compared to the typical volume of 1,558 call options.March 29, 2025 | marketbeat.comLexicon stock soars on Novo Nordisk licensing dealMarch 29, 2025 | za.investing.comLexicon announces exclusive license agreement with Novo Nordisk for LX9851March 29, 2025 | markets.businessinsider.comLexicon announces exclusive license agreement with Novo Nordisk for LX9851March 29, 2025 | markets.businessinsider.comWhat 6 Analyst Ratings Have To Say About Lexicon PharmaceuticalsMarch 29, 2025 | benzinga.comWhat 6 Analyst Ratings Have To Say About Lexicon PharmaceuticalsMarch 29, 2025 | benzinga.comLexicon Pharmaceuticals (LXRX) Soars 95% on Novo Nordisk Licensing DealMarch 28, 2025 | gurufocus.comPenny Stock Lexicon Pharmaceuticals Surges On Obesity Pact Worth $1 Billion With Novo NordiskMarch 28, 2025 | benzinga.comPenny Stock Lexicon Pharmaceuticals Surges On Obesity Pact Worth $1 Billion With Novo NordiskMarch 28, 2025 | benzinga.comLexicon Pharmaceuticals Announces Exclusive License Agreement with Novo Nordisk for LX9851March 28, 2025 | globenewswire.comLexicon Pharmaceuticals (NASDAQ:LXRX) Coverage Initiated by Analysts at StockNews.comStockNews.com assumed coverage on Lexicon Pharmaceuticals in a research report on Thursday. They issued a "sell" rating for the company.March 20, 2025 | marketbeat.comWhat is HC Wainwright's Estimate for LXRX Q1 Earnings?Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Free Report) - HC Wainwright issued their Q1 2025 EPS estimates for shares of Lexicon Pharmaceuticals in a report issued on Friday, March 7th. HC Wainwright analyst J. Pantginis anticipates that the biopharmaceutical company will post earnings per sharMarch 11, 2025 | marketbeat.comEquities Analysts Issue Forecasts for LXRX Q1 EarningsLexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Free Report) - Investment analysts at HC Wainwright issued their Q1 2025 EPS estimates for Lexicon Pharmaceuticals in a report issued on Friday, March 7th. HC Wainwright analyst J. Pantginis anticipates that the biopharmaceutical company will post earnMarch 10, 2025 | marketbeat.com Get Lexicon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for LXRX and its competitors with MarketBeat's FREE daily newsletter. Email Address LXRX Media Mentions By Week LXRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LXRX News Sentiment▼1.140.68▲Average Medical News Sentiment LXRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LXRX Articles This Week▼14▲LXRX Articles Average Week Get Lexicon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for LXRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies GERN News RGLS News ZBIO News MYGN News RIGL News EBS News VSTM News XOMA News VNDA News BOLT News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LXRX) was last updated on 6/10/2025 by MarketBeat.com Staff From Our PartnersBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump Nominates “Next Elon”Elon's Replacement? You've been told Elon Musk has been forced out of DC. But did you know his successor ha...Altimetry | SponsoredGet Ready for Elon Musk’s BIGGEST Comeback YetTesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexicon Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lexicon Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
